Ace Inhibitor
Aggressive management in stage 3 CKD preserves kidney function in diabetes
Some CV medications prescribed less often to women than men
Evidence suggests no COVID-19-related harm from RAAS antagonists
Medicaid expansion improves HF therapy administration for certain racial/ethnic groups

The Affordable Care Act Medicaid Expansion increased receipt of ACE inhibitors, angiotensin II receptor antagonists and angiotensin receptor-neprilysin inhibitors for Hispanic patients hospitalized for HF, according to data presented at the virtual American Heart Association Quality of Care and Outcomes Research Scientific Sessions.
Top stories in cardiology: New trials to further assess hydroxychloroquine, safety of BP medications in COVID-19
Randomized trial underway to assess RAAS inhibitors in COVID-19

Many international medical societies have endorsed the continuation of renin-angiotensin-aldosterone system inhibitors such as ACE inhibitors and angiotensin II receptor antagonists to control BP in patients during the COVID-19 pandemic despite concerns about the drugs’ relationship to ACE2, the receptor that helps the virus bind to cells. Researchers at the University of Pennsylvania Perelman School of Medicine recently started the REPLACE COVID trial to provide more information about the effects of these medications in patients hospitalized with COVID-19.
Endocrine-related targets may drive treatments for COVID-19

Available data assessing the COVID-19 pandemic indicate that case fatality rates are higher among men compared with women, and this distinction becomes more pronounced with advancing age. Little evidence supports theories that a higher prevalence of smoking among men or immune factors can explain the higher death rate among men.
Top stories in cardiology: Societies dispel misinformation about COVID-19, low BP in elderly confers mortality risk
Cardiology societies recommend patients taking ACE inhibitors, ARBs who contract COVID-19 should continue treatment

Several American and European cardiology societies issued statements to dispel misinformation circulating about an association between treatment with renin-angiotensin-aldosterone system antagonists such as ACE inhibitors and angiotensin receptor blockers and increased risk for COVID-19 and increased severity of the disease for those who have contracted COVID-19.